List of Excipients in API amlodipine besylate and celecoxib
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing amlodipine besylate and celecoxib
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| Burke Therapeutics LLC | CONSENSI | amlodipine besylate and celecoxib | 69101-502 | CROSCARMELLOSE SODIUM | 2029-05-22 |
| Burke Therapeutics LLC | CONSENSI | amlodipine besylate and celecoxib | 69101-502 | MAGNESIUM STEARATE | 2029-05-22 |
| Burke Therapeutics LLC | CONSENSI | amlodipine besylate and celecoxib | 69101-502 | MANNITOL | 2029-05-22 |
| Burke Therapeutics LLC | CONSENSI | amlodipine besylate and celecoxib | 69101-502 | POVIDONE K30 | 2029-05-22 |
| Burke Therapeutics LLC | CONSENSI | amlodipine besylate and celecoxib | 69101-502 | SILICON DIOXIDE | 2029-05-22 |
| Burke Therapeutics LLC | CONSENSI | amlodipine besylate and celecoxib | 69101-502 | SODIUM LAURYL SULFATE | 2029-05-22 |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Detailed excipient profiles for amlodipine besylate and celecoxib
Excipient focus: CROSCARMELLOSE SODIUM
amlodipine besylate and celecoxib drug variants containing CROSCARMELLOSE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| Burke Therapeutics LLC | amlodipine besylate and celecoxib | 69101-502 |
| >Company | >Ingredient | >NDC |
amlodipine besylate and celecoxib drug variants not containing CROSCARMELLOSE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| No data available in table | ||
| >Company | >Ingredient | >NDC |
Excipient focus: MAGNESIUM STEARATE
amlodipine besylate and celecoxib drug variants containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| Burke Therapeutics LLC | amlodipine besylate and celecoxib | 69101-502 |
| >Company | >Ingredient | >NDC |
amlodipine besylate and celecoxib drug variants not containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| No data available in table | ||
| >Company | >Ingredient | >NDC |
Excipient focus: MANNITOL
amlodipine besylate and celecoxib drug variants containing MANNITOL
| Company | Ingredient | NDC |
|---|---|---|
| Burke Therapeutics LLC | amlodipine besylate and celecoxib | 69101-502 |
| >Company | >Ingredient | >NDC |
amlodipine besylate and celecoxib drug variants not containing MANNITOL
| Company | Ingredient | NDC |
|---|---|---|
| No data available in table | ||
| >Company | >Ingredient | >NDC |
Excipient focus: POVIDONE K30
amlodipine besylate and celecoxib drug variants containing POVIDONE K30
| Company | Ingredient | NDC |
|---|---|---|
| Burke Therapeutics LLC | amlodipine besylate and celecoxib | 69101-502 |
| >Company | >Ingredient | >NDC |
amlodipine besylate and celecoxib drug variants not containing POVIDONE K30
| Company | Ingredient | NDC |
|---|---|---|
| No data available in table | ||
| >Company | >Ingredient | >NDC |
Excipient focus: SILICON DIOXIDE
amlodipine besylate and celecoxib drug variants containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Burke Therapeutics LLC | amlodipine besylate and celecoxib | 69101-502 |
| >Company | >Ingredient | >NDC |
amlodipine besylate and celecoxib drug variants not containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| No data available in table | ||
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM LAURYL SULFATE
amlodipine besylate and celecoxib drug variants containing SODIUM LAURYL SULFATE
| Company | Ingredient | NDC |
|---|---|---|
| Burke Therapeutics LLC | amlodipine besylate and celecoxib | 69101-502 |
| >Company | >Ingredient | >NDC |
amlodipine besylate and celecoxib drug variants not containing SODIUM LAURYL SULFATE
| Company | Ingredient | NDC |
|---|---|---|
| No data available in table | ||
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2025 - 2026
NCE-1 Patent Challenge Dates 2025 - 2026
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2025, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
